BioLineRx (NASDAQ:BLRX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of BioLineRx in a research note on Wednesday, November 6th.

BioLineRx Price Performance

BLRX stock opened at $0.27 on Friday. The company’s fifty day moving average price is $0.48 and its 200-day moving average price is $0.61. BioLineRx has a one year low of $0.25 and a one year high of $1.89. The company has a market capitalization of $21.72 million, a PE ratio of -0.60 and a beta of 1.48. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. CVI Holdings LLC purchased a new position in shares of BioLineRx in the 2nd quarter valued at about $462,000. PVG Asset Management Corp acquired a new stake in BioLineRx in the second quarter valued at approximately $70,000. Finally, Atria Investments Inc increased its position in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 29,193 shares in the last quarter. 1.56% of the stock is owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.